Compare NEON & ATHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NEON | ATHA |
|---|---|---|
| Founded | 1997 | 2011 |
| Country | Sweden | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.1M | 26.0M |
| IPO Year | 2007 | 2020 |
| Metric | NEON | ATHA |
|---|---|---|
| Price | $1.90 | $6.75 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $6.00 | N/A |
| AVG Volume (30 Days) | 212.9K | ★ 3.2M |
| Earning Date | 11-06-2025 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.54 | N/A |
| Revenue | ★ $2,197,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $43.34 | N/A |
| P/E Ratio | $3.64 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.72 | $2.20 |
| 52 Week High | $29.90 | $8.36 |
| Indicator | NEON | ATHA |
|---|---|---|
| Relative Strength Index (RSI) | 37.68 | 57.44 |
| Support Level | $1.85 | $6.41 |
| Resistance Level | $1.96 | $7.45 |
| Average True Range (ATR) | 0.09 | 0.67 |
| MACD | 0.03 | -0.05 |
| Stochastic Oscillator | 48.48 | 27.14 |
Neonode Inc provides optical sensing solutions for contactless touch, and gesture sensing and also provides software solutions for machine perception that feature machine learning algorithms to detect and track persons and objects in video streams from cameras and other types of imagers. It markets and sells its solutions to customers in many different markets and segments including, office equipment, automotive, industrial automation, medical, military, and avionics. The company geographically operates in the United States, Japan, South Korea, Germany, Sweden, China, and other regions. A majority of its revenue is generated from Japan.
Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) is a small molecule drug candidate designed to enhance the activity of the neurotrophic hepatocyte growth factor (HGF) system; ATH-1020 a novel, orally available, next-generation small molecule drug candidate designed to positively modulate the neurotrophic HGF system; ATH-1105 is a novel, orally available, next-generation, small molecule drug candidate designed to positively modulate the neurotrophic HGF system.